Data / Form D filings / DermBiont, Inc.
DermBiont, Inc.: Form D filings
DermBiont, Inc., a biotechnology company in Boston, MA, filed 12 Form D notices with the SEC between 2019 and 2024. The latest, on November 13, 2024, reports $32.7 million sold of a $45.3 million offering to 72 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 75 KNEELAND ST FL 14, Boston, MA, 02111
- Phone
- (510) 607-8155
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1779253
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2024 | Amendment | $45,312,683 | $32,697,081 | $12,615,602 | 72 | Oct 4, 2023 | sec.gov |
| Oct 19, 2023 | Amendment | $46,755,961 | $19,397,474 | $27,358,487 | 81 | Oct 4, 2023 | sec.gov |
| Oct 19, 2023 | New notice | $37,500,000 | $8,089,121 | $29,410,879 | 10 | Oct 4, 2023 | sec.gov |
| Mar 21, 2023 | New notice | $4,693,564 | $4,693,564 | 69 | Mar 6, 2023 | sec.gov | |
| Sep 19, 2022 | New notice | Indefinite | $2,514,010 | 11 | Sep 6, 2022 | sec.gov | |
| Jan 14, 2022 | New notice | $830,267 | $830,267 | 10 | Dec 30, 2021 | sec.gov | |
| Dec 29, 2021 | New notice | $39,520,131 | $28,845,632 | $10,674,499 | 42 | Dec 17, 2021 | sec.gov |
| Aug 19, 2021 | New notice | $19,171,591 | $19,171,591 | 9 | Aug 4, 2021 | sec.gov | |
| Feb 24, 2021 | New notice | $15,000,000 | $6,550,582 | $8,449,418 | 19 | Feb 12, 2021 | sec.gov |
| Oct 30, 2020 | New notice | $8,000,000 | $7,200,004 | $799,996 | 19 | Oct 16, 2020 | sec.gov |
| Mar 4, 2020 | New notice | $6,000,000 | $2,871,893 | $3,128,107 | 14 | Feb 19, 2020 | sec.gov |
| Jun 11, 2019 | New notice | $8,789,465 | $8,789,465 | 42 | May 31, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Daniel R. Yadegar | Director | |
| Steven R. Basta | Director | |
| Karl R. Beutner | Executive Officer, Director | |
| Nichola R. Eliovits | Executive Officer, Director | |
| Max R. Dawson | Executive Officer | |
| Wilder R. Ramsey | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Nov 11, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what DermBiont, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.